Results 141 to 150 of about 3,681 (204)

内科学(3) [PDF]

, 1986
井上 恭一, 佐々木 博, 小島 隆, 山崎 徹, 市田 隆文, 康山 俊学, 桑原 芳弘, 樋口 清博, 田中 三千雄, 窪田 芳樹, 藤倉 信一郎, 青山 圭一   +11 more
core   +3 more sources

Cost Effectiveness of First-Line Therapies for Treatment-Naïve Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Clin Drug Investig
Woudberg R, Sinanovic E.
europepmc   +1 more source

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study. [PDF]

Blood Adv
Panetta JC, Talleur AC, Naik S, Gottschalk S, Leggas M.   +4 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Virtual Twin Approach for Fludarabine Dosing in Pediatric Hematopoietic Stem Cell Transplantation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Mseddi M, Nath C, Ben Hassine K, Mlakar V, Gloor Y, Gonzales F, Uppugunduri CRS, Daali Y, Keogh S, Ansari M.   +9 more
europepmc   +1 more source

Illuminating Dark Chemical Matter Using the Cell Painting Assay. [PDF]

J Med Chem
Pahl A, Liu J, Patil S, Rezaei Adariani S, Schölermann B, Warmers J, Bonowski J, Koska S, Akbulut Y, Seitz C, Sievers S, Ziegler S, Waldmann H.   +12 more
europepmc   +1 more source

MOG-IgG-associated encephalitis and bronchopneumonia in a child with negative infection screening: a case report and literature review. [PDF]

Front Pediatr
Sun Y, Dong X, Sun M, Wang F, Yu QQ, Yan Y, Cheng N.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Hematologic Abnormalities Associated with Vidarabine

Drug Intelligence & Clinical Pharmacy, 1984
A report of hematologic abnormalities associated with administration of vidarabine in a neonate is presented. High doses of vidarabine (30 mg/kg/d) for the treatment of herpes simplex infection may have caused a decrease in hematocrit and platelet count. This case demonstrates the need to monitor hematologic indices during administration of vidarabine.
Ronald A Lyon
exaly   +3 more sources

Toxicity of Vidarabine

JAMA: The Journal of the American Medical Association, 1979
To the Editor.— Previously we described two patients who were treated with vidarabine (adenine arabinoside) for chronic hepatitis B infection (239:1648, 1978). Since this report we have treated 13 other patients with similar regimens. A summary of side effects related to this drug in all 15 patients follows.
S L, Sacks, J L, Smith, R B, Pollard, V, Sawhney, A S, Mahol, P, Gregory, T C, Merigan, W S, Robinson   +7 more
openaire   +2 more sources

Stability-Indicating Assay for Vidarabine

Journal of Pharmaceutical Sciences, 1979
A physicochemical procedure for the analysis of vidarabine in aqueous parenteral formulations was needed to assure potency and to define stability. Concurrent with the development of this method, its decomposition products and route in aqueous solution were determined.
W H, Hong, D H, Szulczewski
openaire   +2 more sources

Treatment of Vaccinial Keratitis With Vidarabine

Archives of Ophthalmology, 1976
Vaccinial epithelial keratitis was produced in rabbits. When the therapeutic effect of vidarabine on the experimentally-induced disease was evaluated and compared to the effect of idoxuridine, vidarabine was found to be highly effective, substantially more effective than idoxuridine, and nontoxic to the eye.
R A, Hyndiuk, M, Okumoto, R A, Damiano, M, Valenton, G, Smolin   +4 more
openaire   +2 more sources